Detailed explanation of whether Ribociclib has been officially included in domestic medical insurance

Ribociclib, also known as ribociclib, is a CDK4/6 inhibitor used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. As one of the targeted therapeutic drugs, this drug can effectively inhibit the advancement of tumor cell cycle, thereby delaying the proliferation of cancer cells. In recent years, Riboxiclib has been widely used in the international market and has gradually entered the domestic clinical treatment system. At present, the original drug of Riboxil has been officially launched in China and has been included in the national medical insurance drug catalog, which greatly reduces the financial burden for patients who need to take medicine for a long time.

From a price point of view, the domestically marketed Riboxil is an original drug with a specification of 200mg63 tablets per box. The price after medical insurance payment is relatively affordable. In some areas, the actual cost after medical insurance may be as low as about 3,000 yuan, significantly reducing the monthly medication burden. The market retail price before being included in medical insurance is usually around more than 4,000 yuan. In contrast, the price of Riboxil in overseas markets is generally higher. For example, in the European market, the price of the original drug in 200 mg 63 tablets may be as high as more than 20,000 yuan per box, with a significant price gap.

Countries such as India and Laos also provide original and generic drugs of Riboxil at more affordable prices. For example, the price of the original version of Riboxil produced in India is around more than 2,000 yuan, while the generic version produced by Laos Lucius Pharmaceutical Company has a common specification of 200mg*21 tablets, and each box may be sold for more than 1,000 yuan. These generic drugs are similar to the original drugs in terms of drug ingredients and therapeutic effects, making them an economical choice for some patients when purchasing from overseas channels. They are especially suitable for patients who are unable to obtain timely medical insurance reimbursement support in China or who want to reduce treatment costs.

Overall, Riboxil has been successfully included in the domestic medical insurance system, which greatly facilitates the standardized treatment of breast cancer patients. However, considering that medical insurance policies and hospital procurement situations may differ in different regions, it is recommended that patients consult local hospitals or medical insurance departments to obtain the latest medical insurance reimbursement information and price details before actually purchasing drugs. At the same time, patients who plan to purchase drugs from overseas should pay special attention to the formal channels and the reliability of the drug sources to ensure the safety of medication.

Reference materials:https://us.kisqali.com/